| academic journal | Q737498 |
| open-access journal | Q773668 |
| scientific journal | Q5633421 |
| society journal | Q73364223 |
| P6981 | ACNP journal ID | 3314433 |
| P8375 | Crossref journal ID | 179205 |
| P11431 | DBpia journal ID | PLCT00013544 |
| P5115 | Directory of Open Access Journals ID | 2287-2728 |
| 2287-285X | ||
| P8903 | HAL journal ID | 127312 |
| P236 | ISSN | 2287-2728 |
| 2287-285X | ||
| P7363 | ISSN-L | 2287-2728 |
| P1055 | NLM Unique ID | 101586730 |
| P856 | official website | http://e-cmh.org/ |
| https://www.e-cmh.org/ | ||
| http://www.e-cmh.org/ | ||
| P10283 | OpenAlex ID | S2764482685 |
| P3181 | OpenCitations bibliographic resource ID | 309451 |
| P12834 | PMC journal ID | 1864 |
| P7662 | Scilit journal ID | 1759264 |
| P1156 | Scopus source ID | 21100224437 |
| P972 | catalog | Directory of Open Access Journals | Q1227538 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P17 | country | South Korea | Q884 |
| P495 | country of origin | South Korea | Q884 |
| P8875 | indexed in bibliographic review | Scopus | Q371467 |
| Science Citation Index Expanded | Q104047209 | ||
| Korea Citation Index | Q6431606 | ||
| P407 | language of work or name | English | Q1860 |
| P127 | owned by | Korean Association for the Study of the Liver | Q52636133 |
| P123 | publisher | Korean Association for the Study of the Liver | Q52636133 |
| P1476 | title | Clinical and molecular hepatology |
| Q58788714 | 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C |
| Q37343307 | A Korean patient with Guillain-Barré syndrome following acute hepatitis E whose cholestasis resolved with steroid therapy |
| Q41945095 | A case of Alagille syndrome presenting with chronic cholestasis in an adult. |
| Q34779774 | A case of focal nodular hyperplasia with growth progression during pregnancy |
| Q36181211 | A case of hepatoblastoma misdiagnosed as combined hepatocellular carcinoma and cholangiocarcinoma in an adult |
| Q42327996 | A case of levocetirizine-induced liver injury |
| Q42433365 | A case of necrotizing pancreatitis subsequent to transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma. |
| Q33905627 | A case of obstructive jaundice caused by tuberculous lymphadenitis: a literature review. |
| Q41782928 | A case of peripheral gangrene and osteomyelitis secondary to terlipressin therapy in advanced liver disease |
| Q30378731 | A case of portal hypertension by presumed as plexiform neurofibroma at the hepatic hilum |
| Q35231844 | A case of primary hepatic actinomycosis: an enigmatic inflammatory lesion of the liver. |
| Q33873005 | A case of ruptured hepatic angiomyolipoma in a young male |
| Q42944415 | A case of small hepatocellular carcinoma with an extensive lymph node metastasis at diagnosis |
| Q36756389 | A case of variceal bleeding from the jejunum in liver cirrhosis |
| Q91781397 | A challenge in distinguishing between acute hepatitis B and acute exacerbation of chronic hepatitis B |
| Q36153990 | A clinical predictor of varices and portal hypertensive gastropathy in patients with chronic liver disease |
| Q33872982 | A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function |
| Q26752478 | A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016 |
| Q114036893 | A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease |
| Q104470118 | A dilemma that probably would never resolve |
| Q36154001 | A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier |
| Q91987086 | A leap for the journal: Clinical and Molecular Hepatology enters a new era |
| Q30359302 | A lexicon for hepatocellular carcinoma surveillance ultrasonography: benign versus malignant lesions |
| Q36306694 | A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C. |
| Q37488850 | A sclerosing hemangioma of the liver |
| Q36756376 | A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience |
| Q92140595 | A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea |
| Q42173110 | A synchronous hepatocellular carcinoma and renal cell carcinoma treated with radio-frequency ablation |
| Q104470133 | ALCOHOL ASSOCIATED LIVER CIRRHOTICS HAVE HIGHER MORTALITY AFTER INDEX HOSPITALIZATION: LONG-TERM DATA OF 5138 PATIENTS |
| Q33872970 | Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis. |
| Q38781555 | Acute kidney injury in liver cirrhosis: new definition and application |
| Q36779201 | Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C. |
| Q26859067 | Acute-on-chronic liver failure |
| Q99555523 | Acute-on-chronic liver failure as a major predictive factor for mortality in patients with variceal bleeding |
| Q100543927 | Acute-on-chronic liver failure: A predictor of poor prognosis in patients with variceal bleeding or a risk factor for variceal bleeding? |
| Q26752480 | Acute-on-chronic liver failure: a new syndrome in cirrhosis |
| Q50243956 | Adefovir-induced Fanconi syndrome associated with osteomalacia |
| Q36306715 | Adenosquamous carcinoma of the liver |
| Q36983527 | Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients |
| Q64937144 | Advances in ultrasound diagnosis in chronic liver diseases. |
| Q41911314 | Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma |
| Q100543971 | Alcohol and hepatocarcinogenesis |
| Q104470111 | Alcohol-related cirrhosis: the most challenging etiology of cirrhosis is more burdensome than ever |
| Q33905587 | Alcoholic fatty liver disease elevates estimated coronary heart disease risk to levels comparable with those of nonalcoholic fatty liver disease in the Korean population: a cross-sectional study |
| Q38438956 | Allopurinol-induced DRESS syndrome mimicking biliary obstruction |
| Q35231839 | Alteration of laboratory findings after radiofrequency ablation of hepatocellular carcinoma: relationship to severity of the underlying liver disease and the ablation volume |
| Q92319689 | An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection |
| Q43082952 | Angiotensin receptor blocker add-on therapy in portal hypertension: to use angiotensin receptor blocker or not to use, that is the question. |
| Q104470127 | Anti-fibrotic treatments for chronic liver diseases: the present and the future |
| Q30235307 | Anticoagulation in cirrhosis: a new paradigm? |
| Q43199197 | Antitoxin treatment for liver abscess caused by Clostridium perfringens |
| Q36756364 | Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. |
| Q91159698 | Application of transient elastography in nonalcoholic fatty liver disease |
| Q90045142 | Appropriate treatment modality for solitary small hepatocellular carcinoma: Radiofrequency ablation vs. resection vs. transplantation? |
| Q42736702 | Are patients with alcohol-related fatty liver at increased risk of coronary heart disease? |
| Q92611162 | Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis? |
| Q121225345 | Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma |
| Q59352423 | Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level |
| Q36306703 | Association between apolipoprotein E genotype, chronic liver disease, and hepatitis B virus |
| Q57796600 | Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B |
| Q104470123 | Association between new-onset liver cirrhosis and suicide risk in South Korea: A nationwide cohort study |
| Q43818321 | Author’s response to letter to the editor |
| Q100543938 | Autophagy and liver cancer |
| Q38929826 | Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study |
| Q114036892 | Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients |
| Q98461280 | Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease |
| Q26748840 | Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma |
| Q35824096 | Benign nodules mimicking hepatocellular carcinoma on gadoxetic acid-enhanced liver MRI. |
| Q92571935 | Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients |
| Q50077308 | Bilateral optic neuropathy related to severe anemia in a patient with alcoholic cirrhosis: a case report and review of the literature. |
| Q91162087 | Biochemical profile in an infant with neonatal hemochromatosis shows evidence of impairment of mitochondrial long-chain fatty acid oxidation |
| Q64985932 | Biomarker microfibril-associated glycoprotein 4 for non-invasive diagnosis and therapeutic evaluation of hepatic fibrosis in patients with hepatitis C. |
| Q33432267 | Bone marrow metastasis presenting as bicytopenia originating from hepatocellular carcinoma. |
| Q35231849 | Budd-Chiari syndrome with multiple large regenerative nodules. |
| Q90838132 | Can hepatic steatosis really promote hepatitis B viral hepatocarcinogenesis? The jury is out on |
| Q42332098 | Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma? |
| Q91143939 | Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis |
| Q92988844 | Carnitine palmitoyl transferase 1A deficiency in an adult with recurrent severe steato hepatitis aggravated by high pathologic or physiologic demands: A roller-coaster for internists |
| Q41337396 | Caroli's disease misdiagnosed as intraductal papillary neoplasm of the bile duct |
| Q33905593 | Changes in the seroprevalence of IgG anti-hepatitis A virus between 2001 and 2013: experience at a single center in Korea |
| Q38054740 | Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period |
| Q59357694 | Characterization and evaluation of liver fibrosis grade in patients with chronic hepatitis B virus infection and normal transaminases |
| Q42674347 | Chasing after novel non-invasive markers to identify advanced fibrosis in NAFLD. |
| Q34339653 | Chemotherapy induced liver abnormalities: an imaging perspective |
| Q41337317 | Cholangiolocellular carcinoma with satellite nodules showing intermediate differentiation |
| Q60959673 | Cirrhotic cardiomyopathy: An independent prognostic factor for cirrhotic patients |
| Q120147202 | Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and MR imaging |
| Q36756371 | Clinical and epidemiological characteristics of Korean patients with hepatitis C virus genotype 6 |
| Q95650943 | Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years |
| Q26828052 | Clinical applications of transient elastography |
| Q40058881 | Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience. |
| Q91418240 | Clinical characteristics of portal hypertension complicated by gastroesophageal varices in patients with myeloproliferative neoplasms |
| Q30617786 | Clinical features and outcomes of gastric variceal bleeding: retrospective Korean multicenter data |
| Q40961796 | Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion |
| Q33872988 | Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B. |
| Q36154006 | Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection |
| Q55037451 | Clinical implication of hepatic volumetry for living donor liver transplantation. |
| Q38401376 | Clinical implications of advances in liver regeneration |
| Q36518878 | Clinical outcomes of balloon-occluded retrograde transvenous obliteration for the treatment of gastric variceal hemorrhage in Korean patients with liver cirrhosis: a retrospective multicenter study |
| Q100543931 | Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea |
| Q30807184 | Clinical outcomes of transjugular intrahepatic portosystemic shunt for portal hypertension: Korean multicenter real-practice data |
| Q30364978 | Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma. |
| Q64982078 | Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis. |
| Q37229883 | Co-development of autoimmune hepatitis and Sjögren's syndrome triggered by the administration of herbal medicines |
| Q58758202 | Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone? |
| Q89065358 | Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease |
| Q35231826 | Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells |
| Q104470128 | Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis |
| Q36181180 | Comparison and analysis of the prevalence of hepatitis C virus infection by region in the Republic of Korea during 2005-2012. |
| Q96124627 | Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging |
| Q98776757 | Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop |
| Q37606553 | Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma |
| Q91552377 | Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update |
| Q87852472 | Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion |
| Q54233935 | Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion. |
| Q36779207 | Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B |
| Q37343288 | Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment |
| Q36153984 | Comparison of usefulness of clinical diagnostic criteria for hepatocellular carcinoma in a hepatitis B endemic area |
| Q92499645 | Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma |
| Q50046543 | Complete cure of advanced hepatocellular carcinoma with right adrenal gland metastasis and portal vein thrombosis by multiple applications of an interdisciplinary therapy: case report with 8-year follow up. |
| Q39386406 | Complete response of advanced hepatocellular carcinoma to sorafenib : another case and a comprehensive review |
| Q42132430 | Composite liver tumors: a radiologic-pathologic correlation |
| Q36154017 | Concurrent hepatic adenomatoid tumor and hepatic hemangioma: a case report |
| Q45972620 | Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT/MRI system. |
| Q122928498 | Correspondence on Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma” |
| Q121302430 | Correspondence on Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma” |
| Q34779725 | Cost-of-illness studies: concepts, scopes, and methods |
| Q114871338 | Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma |
| Q104470122 | Current and Future Strategies for the Treatment of Chronic Hepatitis C |
| Q30455431 | Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions |
| Q47201402 | Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea. |
| Q41931192 | Current status and strategies for hepatitis B control in Korea. |
| Q41811452 | Current status and strategies for the control of viral hepatitis A in Korea |
| Q41931211 | Current status and strategies for viral hepatitis control in Korea. |
| Q41808225 | Current status of and strategies for hepatitis C control in South Korea |
| Q26745875 | Current status of laparoscopic liver resection for hepatocellular carcinoma |
| Q103829608 | Current understanding of primary biliary cholangitis |
| Q37606541 | Cyanoacrylate injection versus band ligation for bleeding from cardiac varices along the lesser curvature of the stomach |
| Q36306698 | Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma |
| Q41475515 | Decreased C-reactive protein induces abnormal vascular structure in a rat model of liver dysfunction induced by bile duct ligation |
| Q92694056 | Detect or not to detect very early stage hepatocellular carcinoma? The western perspective |
| Q91127462 | Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C |
| Q33873000 | Development of autoimmune hepatitis in a psoriasis patient without immunosuppressive therapy. |
| Q96342323 | Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria? |
| Q104470115 | Direct Comparison of Biopsy Techniques for Hepatic Malignancies |
| Q91439014 | Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter? |
| Q59350694 | Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients |
| Q64281028 | Discussion on critical points for a tailored therapy to cure hepatitis C virus infection |
| Q42343430 | Do cirrhotic patients with a high MELD score benefit from TIPS? |
| Q91781402 | Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis? |
| Q40545890 | Does obesity increase the risk of hepatocellular carcinoma in chronic hepatitis B patients? |
| Q58749406 | Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans? |
| Q91805919 | Drug induced liver injury: East versus West - a systematic review and meta-analysis |
| Q104470117 | Drug-drug interactions with direct-acting antivirals - less is more |
| Q37097608 | Drug-induced liver injury caused by iodine-131 |
| Q24630227 | Drug-induced liver injury: present and future |
| Q37229880 | Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients |
| Q59358188 | Effect of antiviral therapy in reducing perinatal transmission of hepatitis B virus and maternal outcomes after discontinuing them |
| Q36460264 | Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study |
| Q95926076 | Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment |
| Q34779763 | Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension |
| Q92377670 | Effects of different exercise modalities on novel hepatic steatosis indices in overweight women with type 2 diabetes |
| Q64936582 | Effects of zolpidem on sleep parameters in patients with cirrhosis and sleep disturbances: A randomized, placebo-controlled trial. |
| Q37097611 | Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection |
| Q37738808 | Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study |
| Q36983539 | Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study |
| Q41930574 | Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. |
| Q33410974 | Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy |
| Q102989310 | Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study |
| Q57213193 | Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study |
| Q38615384 | Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function. |
| Q64104306 | Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection |
| Q36518868 | Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C. |
| Q35231813 | Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir |
| Q37606534 | Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study). |
| Q38698073 | Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir. |
| Q30448297 | Elevated red cell distribution width is associated with advanced fibrosis in NAFLD. |
| Q42583471 | Elevated serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease |
| Q104470112 | Elimination of Hepatitis C: What would be the practical approach? |
| Q37606559 | Emergency endoscopic variceal ligation in cirrhotic patients with blood clots in the stomach but no active bleeding or stigmata increases the risk of rebleeding |
| Q100296866 | Emerging medical therapies for severe alcoholic hepatitis |
| Q99576834 | Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases |
| Q58562858 | Endoscopic treatment or balloon-occluded retrograde transvenous obliteration is safe for patients with esophageal/gastric varices in Child-Pugh class C end-stage liver cirrhosis |
| Q41978798 | Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASH. |
| Q36181175 | Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy |
| Q95926080 | Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response |
| Q55689881 | Epidemiology of alcoholic liver disease in Korea. |
| Q47564643 | Epidemiology of liver cancer in South Korea |
| Q36311021 | Epithelioid angiomyolipoma of the liver: a case report |
| Q37229890 | Epithelioid hemangioendothelioma of the liver |
| Q36460243 | Erectile dysfunction in patients with liver disease related to chronic hepatitis B |
| Q94372318 | Erratum |
| Q104470119 | Evaluation and Management of Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease |
| Q64892790 | Evaluation of bioenergetic and mitochondrial function in liver transplantation. |
| Q97566838 | Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH |
| Q54230120 | Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals. |
| Q36518911 | Exophytic combined hepatocellular carcinoma and cholangiocarcinoma |
| Q104470134 | Exploring the Mythical Abscopal Effect: Radiation and PD-1 Blockade for Hepatocellular Carcinoma |
| Q90633656 | Extrahepatic manifestations of hepatitis E virus: An overview |
| Q34339590 | Factors affecting drug-induced liver injury: antithyroid drugs as instances |
| Q57293878 | Fatigue and weakness hinder patient social reintegration after liver transplantation |
| Q49670546 | Favorable effect of corticosteroids in treating acute-on-chronic liver failure underlying chronic hepatitis B. |
| Q96635400 | Fecal microbiota transplantation in alcohol related liver diseases |
| Q35231830 | Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma. |
| Q91074546 | Fibrolamellar hepatocellular carcinoma-related hyperammonemic encephalopathy: Up to now and next steps |
| Q36460270 | Focal type of peliosis hepatis |
| Q26777485 | From DCPD to NTCP: the long journey towards identifying a functional hepatitis B virus receptor |
| Q99347723 | From intestinal dysbiosis to alcohol-associated liver disease |
| Q129862849 | Functional cure of CHB encounters resmetirom |
| Q91127486 | Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers |
| Q34339631 | Gastrectomy for the treatment of refractory gastric ulceration after radioembolization with 90Y microspheres |
| Q30235398 | Genetic predisposition in nonalcoholic fatty liver disease |
| Q37229887 | Genotype-4 hepatitis E in a human after ingesting roe deer meat in South Korea |
| Q34779752 | Geographic differences in the epidemiological features of HCV infection in Korea |
| Q100543952 | Global and regional impacts of alcohol use on public health: Emphasis on alcohol policies |
| Q129247262 | Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis |
| Q37343300 | Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis |
| Q36181189 | Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease |
| Q30741676 | HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data. |
| Q100296865 | Hepatic Hippo signaling inhibits development of hepatocellular carcinoma |
| Q37488855 | Hepatic abscess mimicking hepatocellular carcinoma in a patient with alcoholic liver disease |
| Q36306719 | Hepatic angiomyolipoma with minimal fat, mimicking hepatocellular carcinoma |
| Q41810723 | Hepatic inflammatory pseudotumor misinterpreted as hepatocellular carcinoma |
| Q36518916 | Hepatic metastases from hepatoid adenocarcinoma of stomach mimicking hepatocellular carcinoma |
| Q37738810 | Hepatic perivascular epithelioid cell tumor (PEComa): a case report with a review of literatures |
| Q37711328 | Hepatic venous pressure gradient: clinical use in chronic liver disease |
| Q91916229 | Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand |
| Q34339613 | Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B. |
| Q37343296 | Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B. |
| Q36154011 | Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience |
| Q28283484 | Hepatitis C virus and hepatocarcinogenesis |
| Q35824070 | Hepatitis C virus infection in patients with hemophilia in Korea: Is antiviral therapy effective and safe? |
| Q35824057 | Hepatitis C virus-induced hepatocellular carcinoma |
| Q36756358 | Hepatitis C virus: virology and life cycle |
| Q39754997 | Hepatocellular carcinoma composed of two different histologic types: imaging features on gadoxetic acid-enhanced liver MRI. |
| Q92079458 | Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm? |
| Q37738802 | Hepatogastric fistula as a rare complication of pyogenic liver abscess |
| Q43105818 | Hepatoid adenocarcinoma of the stomach: an unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma |
| Q36756380 | High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice |
| Q33424281 | Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea |
| Q48341552 | Histopathological evaluation of liver fibrosis and cirrhosis regression |
| Q37343293 | Histopathology of a benign bile duct lesion in the liver: Morphologic mimicker or precursor of intrahepatic cholangiocarcinoma |
| Q91127466 | How does hepatic steatosis affect the outcome of patients with chronic hepatitis B? |
| Q96295667 | How does low-level viremia affect the prognosis of patients with chronic hepatitis B? |
| Q99606417 | How long should physicians follow up with patients after curative treatment for hepatocellular carcinoma? |
| Q92680311 | Hyperammonemic encephalopathy: An unusual presentation of fibrolamellar hepatocellular carcinoma |
| Q48217549 | Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. |
| Q36181205 | Imaging findings for intravascular large B-cell lymphoma of the liver |
| Q26771777 | Imaging findings of mimickers of hepatocellular carcinoma |
| Q92606381 | Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation |
| Q37343317 | Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection |
| Q126282596 | Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma |
| Q36460260 | Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: A 4-year retrospective cohort study |
| Q33905617 | Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation |
| Q35824075 | Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients |
| Q42433381 | Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients |
| Q36756383 | Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE. |
| Q38120248 | Important predictor of mortality in patients with end-stage liver disease |
| Q37711332 | Improved severe hepatopulmonary syndrome after liver transplantation in an adolescent with end-stage liver disease secondary to biliary atresia |
| Q37711325 | Inactıve hepatitis B surface antigen carriers and intrafamilial tramsmission: results of a 10-year study |
| Q91963150 | Incidence and risk factors of dysphagia after variceal band ligation |
| Q38822712 | Influence of P53 on the radiotherapy response of hepatocellular carcinoma. |
| Q59351245 | Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir |
| Q90825962 | Influence of some methylated hepatocarcinogenesis-related genes on the response to antiviral therapy and development of fibrosis in chronic hepatitis C patients |
| Q41952117 | Influence of ultrasound contrast agents on spectral Doppler analysis in recipients of liver transplantation |
| Q98631873 | Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcino- ma through the Snail/GSK-3/beta-catenin pathway |
| Q41337554 | Inhibition of hepatic stellate cells by bone marrow-derived mesenchymal stem cells in hepatic fibrosis. |
| Q100543944 | Inter-professional and inter-departmental alcoholism rehabilitation program |
| Q54258450 | Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling. |
| Q39974780 | Intraductal malignant tumors in the liver mimicking cholangiocarcinoma: Imaging features for differential diagnosis |
| Q43089472 | Intrahepatic bile duct adenoma in a patient with chronic hepatitis B accompanied by elevation of alpha-fetoprotein |
| Q34779779 | Intrahepatic cholangiocarcinoma arising in Caroli's disease |
| Q33905633 | Intrahepatic cholangiocarcinoma with predominant ductal plate malformation pattern |
| Q90363571 | Intricate interpretation of etiology-specific outcome comparison in patients with hepatocellular carcinoma |
| Q40961740 | Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign? |
| Q34779745 | Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C? |
| Q48190133 | Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice? |
| Q97528115 | Is liver biopsy still useful in the era of non-invasive tests? |
| Q43199205 | Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C? |
| Q37738812 | Is scheduled second chemoembolization necessary for early stage hepatocellular carcinoma showing complete response after first chemoembolization? |
| Q97528130 | Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? |
| Q41931198 | Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus? |
| Q40667507 | Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B? |
| Q36153972 | Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis? |
| Q55709396 | Journal metrics of Clinical and Molecular Hepatology based on the Web of Science Core Collection. |
| Q36153966 | KASL Clinical Practice Guidelines: Management of chronic hepatitis B. |
| Q89502154 | KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications |
| Q92522263 | KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications |
| Q64897844 | KASL clinical practice guidelines for management of chronic hepatitis B. |
| Q37229858 | KASL clinical practice guidelines: management of alcoholic liver disease |
| Q26752475 | KASL clinical practice guidelines: management of chronic hepatitis B |
| Q26752471 | KASL clinical practice guidelines: management of hepatitis C |
| Q51836024 | KASL clinical practice guidelines: management of hepatitis C. |
| Q37488800 | KASL clinical practice guidelines: management of nonalcoholic fatty liver disease |
| Q104470131 | Lactobacillus attenuates progression of non-alcoholic fatty liver disease by lowering cholesterol and steatosis |
| Q37229870 | Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients |
| Q48229827 | Lamivudine: fading into the mists of time. |
| Q99708641 | Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated "enemy"? |
| Q121734735 | Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma” |
| Q122456582 | Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma” |
| Q33872993 | Life-sustaining treatment and palliative care in patients with liver cirrhosis - legal, ethical, and practical issues |
| Q91647766 | Limited expression of TLR9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease |
| Q90463251 | Limited expression of toll-like receptor 9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease |
| Q40148105 | Liver dysfunction induced by systemic hypersensitivity reaction to lamotrigine: case report |
| Q97528082 | Liver graft from donation after circulatory death donor: Real practice to improve graft viability |
| Q31108230 | Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm. |
| Q36779171 | Liver metastasis of meningeal hemangiopericytoma: a study of 5 cases. |
| Q42740002 | Liver stiffness measurement: is it a non-invasive substitution for HVPG? |
| Q39484651 | Liver transplantation for acute-on-chronic liver failure from erythropoietic protoporphyria. |
| Q28074653 | Liver transplantation for advanced hepatocellular carcinoma |
| Q100543955 | Liver-lung axes in alcohol-related liver disease |
| Q47694320 | Living-donor liver transplantation for giant hepatic hemangioma with diffuse hemangiomatosis in an adult: a case report |
| Q100543965 | Long non-coding RNAs in liver diseases: Focusing on nonalcoholic fatty liver disease, alcohol-related liver disease, and cholestatic liver disease |
| Q130261134 | Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: a multi-nationwide cohort study from South Korea, Japan, and the UK |
| Q36181200 | Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy |
| Q34339608 | Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir |
| Q99576837 | Long-term prognosis and management of hepatocellular carcinoma after curative treatment |
| Q42669168 | Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient |
| Q95932320 | Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir |
| Q96635404 | Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change? |
| Q96635402 | Macro-aspartate aminotransferase in a healthy woman |
| Q33905639 | Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib |
| Q30386029 | Magnetization-tagged MRI is a simple method for predicting liver fibrosis. |
| Q47550875 | Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend |
| Q39024201 | Management of direct antiviral agent failures. |
| Q52653838 | Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals. |
| Q96635406 | Management of liver diseases during the pandemic of coronavirus disease-19 |
| Q37711308 | Management of portal hypertensive gastropathy and other bleeding |
| Q34779730 | Management of viral hepatitis in liver transplant recipients |
| Q26777480 | Managing alcoholic liver disease |
| Q100543915 | Managing liver cirrhotic complications: Overview of esophageal and gastric varices |
| Q40234290 | Meta-analysis of the correlation between the rs17401966 polymorphism in kinesin family member 1B and susceptibility to hepatitis B virus related hepatocellular carcinoma. |
| Q104470113 | Metabolic disease as a risk of hepatocellular carcinoma |
| Q40155424 | Metastatic endophthalmitis and thyroid abscess complicating Klebsiella pneumoniae liver abscess. |
| Q47264110 | Microbiota, a key player in alcoholic liver disease. |
| Q99615284 | More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis |
| Q91310128 | Multimodal sequential treatment for occluded TIPS: Case report and review of literature |
| Q36518896 | Multiplex polymerase chain reaction test for the diagnosis of acute viral hepatitis A. |
| Q37097604 | Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis |
| Q38791719 | NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs |
| Q104470124 | Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B |
| Q37606546 | New perspectives of biomarkers for the management of chronic hepatitis B. |
| Q35824064 | New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis |
| Q26771779 | Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase |
| Q33905607 | No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients |
| Q28080136 | Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment |
| Q100543968 | Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights |
| Q114036894 | Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time? |
| Q37229854 | Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis |
| Q42000376 | Noninvasive diagnosis of hepatocellular carcinoma |
| Q43238983 | Noninvasive diagnostic criteria for hepatocellular carcinoma |
| Q43073218 | Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis |
| Q36983514 | Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease |
| Q96342321 | Novel biomarkers for the management of chronic hepatitis B |
| Q99555522 | Obesity and binge alcohol intake are deadly combination to induce steatohepatitis: A model of high-fat diet and binge ethanol intake |
| Q37343284 | Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B. |
| Q102385928 | Obesity and the risk of primary liver cancer: A systematic review and meta-analysis |
| Q42944405 | Occult hepatitis B virus infection: clearance or disguise? |
| Q104560897 | Old HBV Never Dies; It Just Hides Itself within the Host Genome |
| Q90219968 | Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report |
| Q97528122 | Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma |
| Q104470125 | Optimizing the management of intermediate-stage HCC: current trends and prospects |
| Q37229851 | Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade |
| Q104470109 | Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care |
| Q30434752 | Overview and recent trends of systematic reviews and meta-analyses in hepatology |
| Q100543961 | Oxidative stress and glutamate excretion in alcoholic steatosis: Metabolic synapse between hepatocyte and stellate cell |
| Q43211342 | P53 expression in hepatocellular carcinoma: influence on the radiotherapeutic response of the hepatocellular carcinoma |
| Q57297321 | Pathologic differential diagnosis of metastatic carcinoma in the liver |
| Q33429204 | Peliosis hepatis presenting with massive hepatomegaly in a patient with idiopathic thrombocytopenic purpura |
| Q30364975 | Percutaneous cryoablation for hepatocellular carcinoma |
| Q37488838 | Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B. |
| Q104470132 | Persistence of intrahepatic HBV DNA integration in patients developing hepatocellular carcinoma after HBsAg seroclearance |
| Q91814543 | Persistent elevation of aminotransferases in liver transplant in association with chronic norovirus infection |
| Q26777483 | Personalized management of cirrhosis by non-invasive tests of liver fibrosis |
| Q35231805 | Personalized treatment of hepatitis B. |
| Q99555521 | Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma? |
| Q47280001 | Picroside II attenuates fatty acid accumulation in HepG2 cells via modulation of fatty acid uptake and synthesis |
| Q40135381 | Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world? |
| Q38415645 | Portal biliopathy treated with endoscopic biliary stenting |
| Q43211325 | Portal flow steal after liver transplantation |
| Q92531321 | Portal pressure gradient and serum albumin: A simple combined parameter associated with the appearance of ascites in decompensated cirrhosis treated with transjugular intrahepatic portosystemic shunt |
| Q99243204 | Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology |
| Q37488818 | Predicting factors of present hepatitis C virus infection among patients positive for the hepatitis C virus antibody. |
| Q26823671 | Prediction of fibrosis progression in chronic viral hepatitis |
| Q30407182 | Predictive factors of contrast-enhanced ultrasonography for the response to transarterial chemoembolization in hepatocellular carcinoma |
| Q36983516 | Predictive factors that influence the survival rates in liver cirrhosis patients with spontaneous bacterial peritonitis |
| Q34779758 | Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection |
| Q100543948 | Predictors of steroid non-response and new approaches in severe alcoholic hepatitis |
| Q37606544 | Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization |
| Q36181185 | Preference elicitation approach for measuring the willingness to pay for liver cancer treatment in Korea |
| Q33905612 | Prevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal |
| Q49717262 | Prevention and management of gastroesophageal varices. |
| Q26747023 | Prevention of Hepatitis B reactivation in the setting of immunosuppression |
| Q37606528 | Primary adenosquamous carcinoma of the liver: a case report |
| Q37229894 | Primary hepatic lymphoma mimicking acute hepatitis |
| Q39974862 | Primary squamous cell carcinoma of the liver: a case report |
| Q104470116 | Probiotics for treatment of nonalcoholic fatty liver disease: it's worth a try |
| Q129454799 | Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study |
| Q58753068 | Prognostic implications of trunk muscle mass in liver cirrhosis |
| Q36518882 | Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score |
| Q99576836 | Programmed cell death in alcohol-associated liver disease |
| Q40116780 | Protein and vitamin B6 intake are associated with liver steatosis assessed by transient elastography, especially in obese individuals |
| Q36983555 | Pseudocirrhosis as a complication after chemotherapy for hepatic metastasis from breast cancer |
| Q33905622 | Pure red-cell aplasia and autoimmune hemolytic anemia in a patient with acute hepatitis A. |
| Q104100427 | Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study |
| Q33872976 | Radioembolization for the treatment of hepatocellular carcinoma |
| Q30439812 | Radiofrequency ablation of very-early-stage hepatocellular carcinoma inconspicuous on fusion imaging with B-mode US: value of fusion imaging with contrast-enhanced US. |
| Q64993911 | Radiomics and radiogenomics of primary liver cancers. |
| Q36756398 | Reactive lymphoid hyperplasia of the liver |
| Q30415186 | Recent advances in the imaging of hepatocellular carcinoma |
| Q48348464 | Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma |
| Q57170235 | Recent research trends and updates on nonalcoholic fatty liver disease |
| Q54223871 | Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL. |
| Q104132009 | Recent updates on the management of autoimmune hepatitis |
| Q37606536 | Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban |
| Q37229866 | Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea. |
| Q37343311 | Regression of esophageal varices and splenomegaly in two patients with hepatitis-C-related liver cirrhosis after interferon and ribavirin combination therapy |
| Q36779177 | Regression of esophageal varices during entecavir treatment in patients with hepatitis-B-virus-related liver cirrhosis |
| Q42669217 | Regression of liver cirrhosis: orthodoxy or paradigm shift? |
| Q89878264 | Regulated differentiation of stem cells into an artificial 3D liver as a transplantable source |
| Q60960828 | Rehabilitation for social reintegration in liver transplant patients |
| Q36518891 | Relationship between the hepatic venous pressure gradient and first variceal hemorrhage in patients with cirrhosis: a multicenter retrospective study in Korea |
| Q113700645 | Repurposing drugs to target NASH: Auranofin- a gold-organic molecule complex for the treatment of a complex trait |
| Q33905600 | Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus |
| Q47861914 | Resection plane-dependent error in computed tomography volumetry of the right hepatic lobe in living liver donors |
| Q35824081 | Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes |
| Q40175933 | Reversible splenial lesion on the corpus callosum in nonfulminant hepatitis A presenting as encephalopathy |
| Q104470126 | Review: The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future |
| Q92410193 | Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B |
| Q33872964 | Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B. |
| Q34339577 | Risk stratification of HBV infection in Asia-Pacific region. |
| Q37711314 | Role of 15-hydroxyprostaglandin dehydrogenase down-regulation on the prognosis of hepatocellular carcinoma. |
| Q96124633 | Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis |
| Q90675216 | Role of endoscopic treatment or balloon-occluded retrograde transvenous obliteration in patients with Child-Pugh class C end-stage liver cirrhosis and esophageal/gastric varices |
| Q50115795 | Role of liver transplantation in severe alcoholic hepatitis |
| Q100543957 | Roles of the complement system in alcohol-induced liver disease |
| Q64086795 | Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization |
| Q34339626 | Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation |
| Q34779767 | Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis |
| Q36181216 | Sarcomatoid cholangiocarcinoma with osteoclast-like giant cells associated with hepatolithiasis: A case report |
| Q34339646 | Sarcomatoid hepatocellular carcinoma with mixed osteoclast-like giant cells and chondroid differentiation |
| Q100543919 | Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma |
| Q90045152 | Sarcopenia: Ammonia metabolism and hepatic encephalopathy |
| Q104470130 | Scaling up the in-hospital HCV care cascade in Taiwan |
| Q91283177 | Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard |
| Q93057152 | Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection |
| Q36518887 | Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease |
| Q92377666 | Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease |
| Q112295918 | Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis |
| Q47389190 | Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis. |
| Q34779739 | Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B. |
| Q57790843 | Severe acute alcoholic hepatitis and liver transplant: A never-ending mournful story |
| Q41842297 | Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome. |
| Q36518900 | Severe steatohepatitis with hepatic decompensation resulting from malnutrition after pancreaticoduodenectomy |
| Q91781387 | Should physicians go out of the way to differentiate between acute hepatitis B and acute exacerbation of chronic hepatitis B? |
| Q90240892 | Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease? |
| Q104470135 | Significant down-regulation of GHR expression as a new unfavorable prognostic factor in HCV-related hepatocellular carcinoma revealed |
| Q129137049 | Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease |
| Q37711334 | Sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy. |
| Q36460249 | Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea |
| Q36154023 | Solitary necrotic nodule of the liver. |
| Q38836579 | Sonography of hepatic hemangioma accompanied by arterioportal shunt |
| Q42433367 | Spinal cord injury after conducting transcatheter arterial chemoembolization for costal metastasis of hepatocellular carcinoma |
| Q34339599 | Spontaneous HBsAg loss in Korean patients: relevance of viral genotypes, S gene mutations, and covalently closed circular DNA copy numbers |
| Q36181170 | Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure |
| Q128786597 | Steatotic liver disease: Know your enemies |
| Q97528090 | Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial |
| Q50034659 | Strategic Application of Radiotherapy for Hepatocellular Carcinoma |
| Q99347722 | Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients |
| Q41776159 | Surveillance of hepatocellular carcinoma: is only ultrasound enough? |
| Q36779194 | Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis |
| Q37606550 | Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination? |
| Q92638598 | Switching to systemic therapy after locoregional treatment failure: Definition and best timing |
| Q100543923 | Targeting epithelial-mesenchymal transition pathway in hepatocellular carcinoma |
| Q35231822 | Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients |
| Q30860824 | Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. |
| Q37738814 | Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients |
| Q36067839 | Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases |
| Q100543935 | The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC) |
| Q90692081 | The Association of leptin with severity of non-alcoholic fatty liver disease: A population-based study |
| Q104470129 | The Cut-Off Value of Transient Elastography to the Value of Hepatic Venous Pressure Gradient in Alcoholic Cirrhosis |
| Q37488806 | The MR imaging diagnosis of liver diseases using gadoxetic acid: emphasis on hepatobiliary phase |
| Q37711322 | The Refit model for end-stage liver disease-Na is not a better predictor of mortality than the Refit model for end-stage liver disease in patients with cirrhosis and ascites |
| Q28075923 | The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy |
| Q97528097 | The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma |
| Q36153978 | The clinical features of drug-induced liver injury observed through liver biopsy: focus on relevancy to autoimmune hepatitis |
| Q34339621 | The comparison of esophageal variceal ligation plus propranolol versus propranolol alone for the primary prophylaxis of esophageal variceal bleeding |
| Q30921988 | The cost of liver disease in Korea: methodology, data, and evidence |
| Q104470110 | The cutoff of transient elastography for the evaluation of portal hypertension should be different according to the etiology? |
| Q91781390 | The dilemma of differentiating between acute hepatitis B and chronic hepatitis B with acute exacerbation: Is quantitative serology the answer? |
| Q99708640 | The effect of moderate alcohol drinking in nonalcoholic fatty liver disease |
| Q37097615 | The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy |
| Q35231817 | The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B. |
| Q92724554 | The fibrogenic process and the unleashing of acute-on-chronic liver failure |
| Q128665343 | The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective |
| Q36460256 | The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunction |
| Q37711317 | The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients |
| Q36983522 | The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults |
| Q37488822 | The levels of liver enzymes and atypical lymphocytes are higher in youth patients with infectious mononucleosis than in preschool children |
| Q99576835 | The lymphatic system in alcohol-associated liver disease |
| Q36983561 | The lymphatic vascular system in liver diseases: its role in ascites formation |
| Q92687098 | The management of polycystic liver disease by tolvaptan |
| Q26777478 | The mutational landscape of hepatocellular carcinoma |
| Q38074434 | The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension |
| Q37738796 | The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. |
| Q104132010 | The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease |
| Q37229874 | The secondary prophylactic efficacy of beta-blocker after endoscopic gastric variceal obturation for first acute episode of gastric variceal bleeding |
| Q36779181 | The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease |
| Q37738804 | The use of immunosuppression in autoimmune hepatitis: A current literature review |
| Q30407178 | The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study |
| Q30741669 | The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data |
| Q30452578 | The usefulness of transient elastography, acoustic-radiation-force impulse elastography, and real-time elastography for the evaluation of liver fibrosis |
| Q37488846 | Three cases of glycogenic hepatopathy mimicking acute and relapsing hepatitis in type I diabetes mellitus |
| Q33403977 | Thrombocytopenia represents a risk for deterioration of liver function after radiofrequency ablation in patients with hepatocellular carcinoma |
| Q90463010 | Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis? |
| Q26771776 | Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future |
| Q37097620 | Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma |
| Q64963847 | Transarterial embolization for the treatment of complicated liver hemangiomas: A report of two cases and review of the literature. |
| Q41846141 | Transient elastography can be integrated into routine clinical practice for the evaluation of portal hypertension? |
| Q36298209 | Transient elastography versus hepatic venous pressure gradient for diagnosing portal hypertension: a systematic review and meta-analysis |
| Q92851677 | Transjugular intrahepatic portosystemic shunt assisted with trans-splenic access |
| Q47832831 | Treatment options after sorafenib failure in patients with hepatocellular carcinoma. |
| Q91074549 | Trends in the prevalence of chronic liver disease in the Korean adult population, 1998-2017 |
| Q39754936 | Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. |
| Q36306710 | Type and cause of liver disease in Korea: single-center experience, 2005-2010. |
| Q112573237 | U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases |
| Q91514124 | Ultraselective conventional transarterial chemoembolization: When and how? |
| Q37488828 | Ultrasonographic scoring system score versus liver stiffness measurement in prediction of cirrhosis. |
| Q90008725 | Underlying liver disease and advanced stage liver cancer are associated with elevated neutrophil-lymphocyte ratio |
| Q37097600 | Undifferentiated embryonal sarcoma of the liver in an adult patient |
| Q64964316 | Unmet need in chronic hepatitis B management. |
| Q90434504 | Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy |
| Q91669625 | Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure |
| Q102149045 | Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective |
| Q98776756 | Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment |
| Q48096472 | Use of sofosbuvir in chronic kidney disease: Is it necessary? |
| Q91299764 | VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature |
| Q90349255 | Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line |
| Q43089477 | What we know about paracentesis induced circulatory dysfunction? |
| Q30372310 | What we need to know when performing and interpreting US elastography. |
| Q104470120 | β-blockers in advanced cirrhosis: more friend than enemy |
| Q36983551 | β-catenin activated hepatocellular adenoma |
| Q52636133 | Korean Association for the Study of the Liver | house publication | P2813 |
Search more.